Amneal Pharmaceuticals Inc

In Stage 2 advance, the stock remains in a healthy uptrend across medium- and long-term horizons, but short-term consolidation around key EMAs and neutral momentum require patience. Execution readiness is neutral, favoring a waiting posture until a pullback toward support or decisive breakout offers a clearer entry. Overall, maintain bullish bias but stalk for favorable execution zones.

• ↑Q2 2026 revenue $796M (+10% YoY) and adjusted EBITDA $206M (+12% YoY) highlight strong execution.
• ↑Gross margin rose to 46.2% (+60 bps YoY) on favorable product mix and efficiencies.
• ↓Specialty segment forecast flat growth in 2026 due to Parkinson’s generic erosion.